Table 4.
Spectrum of activity of different Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors for different resistance mutations, as studied by Gainor et al. using in vitro data on cell lines [84].
| ALK Mutation | Crizotinib | Ceritinib | Alectinib | Brigatinib | Lorlatinib |
|---|---|---|---|---|---|
| V1 | S | S | S | S | S |
| C1156Y | I | S | S | S | S |
| I1171N | I | S | R | S | S |
| I1171S | I | S | I | S | S |
| I1171T | I | S | S | S | S |
| F1174C | I | S | S | S | S |
| L1196M | R | S | I | S | S |
| L1198F | S | I | S | S | S |
| G1202R | R | I | R | I | S |
| G1202del | I | I | I | I | S |
| D1203N | I | S | S | S | S |
| E1210K | S | S | S | S | S |
| G1269A | I | S | S | No data | S |
| D1203N + F1174C | R | R | I | I | I |
| D1203N + E1210K | I | I | I | I | S |
* R: resistant; S: sensitive; I: intermediate.